Albert A Davis

List of Publications by Year
in descending order

26 papers	882 citations	759233 12 h-index	794594 19 g-index
29 all docs	29 docs citations	29 times ranked	1767 citing authors

#	Article	IF	Citations
1	Solving neurodegeneration: common mechanisms and strategies for new treatments. Molecular Neurodegeneration, 2022, 17, 23.	10.8	83
2	VCP suppresses proteopathic seeding in neurons. Molecular Neurodegeneration, 2022, 17, 30.	10.8	15
3	Is Levodopa Response a Valid Indicator of Parkinson's Disease?. Movement Disorders, 2021, 36, 948-954.	3.9	26
4	MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. Annals of Clinical and Translational Neurology, 2021, 8, 1817-1830.	3.7	11
5	A QuICR test to diagnose Parkinsonâ€™s disease. Science Translational Medicine, 2021, 13, .	12.4	0
6	Astrocytic BMAL1 regulates protein aggregation in mouse models of alphaâ€synuclein and tau pathology. Alzheimer's and Dementia, 2021, 17, e058631.	0.8	0
7	Overlapping genetic architecture between Parkinson disease and melanoma. Acta Neuropathologica, 2020, 139, 347-364.	7.7	23
8	TDP-43 dysfunction results in R-loop accumulation and DNA replication defects. Journal of Cell Science, 2020, 133, .	2.0	35
9	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	5.2	8
10	Tau kinetics in Alzheimer disease and primary tauopathies. Alzheimer's and Dementia, 2020, 16, e039109.	0.8	0
11	APOE genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	12.4	102
12	Leaky pipes: Tau and apoE implicated in blood-brain barrier dysfunction in Alzheimer disease. Science Translational Medicine, 2020, 12, .	12.4	6
13	In on the ground floor: T cells respond to Î±-synuclein in preclinical Parkinsonâ€™s disease. Science Translational Medicine, 2020, 12, .	12.4	0
14	Beyond synuclein: Organelle accumulation in Lewy bodies may drive neurodegeneration. Science Translational Medicine, 2020, 12, .	12.4	1
15	Plasma proteins have a ticket to ride the blood-brain barrier. Science Translational Medicine, 2020, 12, .	12.4	0
16	Partners in crime: Î±-synuclein modulates pathologic tau spreading. Science Translational Medicine, 2020, 12, .	12.4	0
17	A Systematic Review and Case Series of Ziprasidone for Psychosis in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2019, 9, 63-71.	2.8	9
18	Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices. Neurocritical Care, 2018, 29, 225-232.	2.4	8

#	Article	IF	Citations
19	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. Annual Review of Cell and Developmental Biology, 2018, 34, 545-568.	9.4	99
20	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in Neuroscience, 2018, 12, 230.	2.8	21
21	Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-Î² and other amyloidogenic proteins. Journal of Lipid Research, 2017, 58, 824-836.	4.2	159
22	TMEM230 in Parkinson's disease. Neurobiology of Aging, 2017, 56, 212.e1-212.e3.	3.1	9
23	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurology, 2017, 17, 198.	1.8	55
24	Parkinson disease and cognitive impairment. Neurology: Clinical Practice, 2016, 6, 452-458.	1.6	34
25	Resequencing analysis of five Mendelian genes andÂthe top genes from genome-wide association studies in Parkinsonâ€™s Disease. Molecular Neurodegeneration, 2016, 11, 29.	10.8	70
26	Variants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiology of Aging, 2016, 37, 209.e1-209.e7.	3.1	106